Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.
每年兩次使用 depemokimab 治療慢性鼻竇炎合併鼻息肉的療效與安全性(ANCHOR-1 和 ANCHOR-2):第三期、隨機、雙盲、平行試驗。
Lancet 2025-03-04
Trends in the global, regional, and national burden of oral conditions from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021.
1990年至2021年全球、區域及國家口腔疾病負擔的趨勢:2021年全球疾病負擔研究的系統分析。
Lancet 2025-03-02
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.
高風險復發患者使用減量與全劑量直接口服抗凝劑延長治療靜脈血栓栓塞的非劣效性多中心隨機開放標籤盲端點試驗。
Lancet 2025-03-01
The African Critical Illness Outcomes Study (ACIOS): a point prevalence study of critical illness in 22 nations in Africa.
非洲重症疾病結果研究 (ACIOS):22個非洲國家的重症疾病點流行病學研究。
Lancet 2025-03-01
Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.
直接口服抗凝劑與不使用抗凝劑在房顫腦內出血倖存者中預防中風的比較 (PRESTIGE-AF):一項多中心、開放標籤、隨機、第三期試驗。
Lancet 2025-03-01
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
利用常規可用的臨床特徵來優化2型糖尿病處方的五藥類模型:預測模型的開發與驗證研究。
Lancet 2025-02-28
Medicaid Spending and Health-Related Social Needs in the North Carolina Healthy Opportunities Pilots Program.
北卡羅來納州健康機會試點計畫中的Medicaid支出與健康相關社會需求。
JAMA 2025-02-27